Effectiveness of oral pre-exposure prophylaxis (PrEP) for HIV
Abstract
Key take-home messages
- Oral PrEP (tenofovir disoproxil fumarate with emtricitabine) is highly protective against HIV acquisition across various populations and across different dosing schedules.
- Open label and demonstration projects in both high- and low-income country settings have shown that oral tenofovir disoproxil fumarate with or without emtricitabine as PrEP can be delivered feasibly within existing health systems.
- The protective efficacy of oral PrEP (tenofovir disoproxil fumarate with or without emtricitabine) for HIV prevention is highly dependent on adherence to the prescribed regimen.
- Extremely rare cases of HIV infection with optimal adherence have been reported when transmission of drug-resistant mutations or atypical patterns of seroconversion have occurred.
Authors
The Ontario HIV Treatment Network: Rapid Response Service
Year
2018
Topics
- Population(s)
- Men who have sex with men
- Women
- Children or Youth (less than 18 years old)
- People who use drugs
- Heterosexual men
- General HIV+ population
- General HIV- population
- Prevention
- Biomedical interventions
